Effect of 2 psychotherapies on depression and disease activity in pediatric Crohn's disease

Eva Szigethy, Ada O Youk, Joseph Gonzalez-Heydrich, Simona I Bujoreanu, John Weisz, Diane Fairclough, Peter Ducharme, Neil Jones, Francis Lotrich, David Keljo, Arvind Srinath, Athos Bousvaros, David Kupfer, David R DeMaso, Eva Szigethy, Ada O Youk, Joseph Gonzalez-Heydrich, Simona I Bujoreanu, John Weisz, Diane Fairclough, Peter Ducharme, Neil Jones, Francis Lotrich, David Keljo, Arvind Srinath, Athos Bousvaros, David Kupfer, David R DeMaso

Abstract

Background: Crohn's disease (CD) is associated with depression. It is unclear if psychosocial interventions offer benefit for depressive symptoms during active CD. In this secondary analysis of a larger study of treating depression in pediatric inflammatory bowel disease, we assessed whether cognitive behavioral therapy (CBT) would differentiate from supportive nondirective therapy in treating depression and disease activity in youth with CD. We also explored whether somatic depressive symptoms showed a different pattern of response in the overall sample and the subset with active inflammatory bowel disease.

Methods: Youth with depression and CD (n = 161) were randomized to 3 months of CBT (teaching coping skills) or supportive nondirective therapy (supportive listening). Depressive severity was measured using the Children's Depression Rating Scale-Revised (CDRS-R) with the somatic depressive subtype consisting of those CDRS-R items, which significantly correlated with CD activity. Disease activity was measured by the Pediatric Crohn's disease Activity Index. Given the potential confound of higher dose steroids, subanalyses excluded subjects on >20 mg/d prednisone equivalent (n = 34).

Results: Total CDRS-R scores in the overall sample significantly decreased over time after both treatments (P < 0.0001). Treatment with CBT was associated with a significantly greater improvement in the Pediatric Crohn's disease Activity Index (P = 0.05) and somatic depressive subtype (P = 0.03) in those with active inflammatory bowel disease (n = 95) compared with supportive nondirective therapy. After excluding those on steroids (n = 34), there was a significant improvement in total CDRS-R (P = 0.03) and in Pediatric Crohn's disease Activity Index (P = 0.03) after CBT.

Conclusions: Psychotherapy may be a useful adjunct to treat depression in the context of CD-related inflammation in youth who are not concurrently on higher dose steroids.

Trial registration: ClinicalTrials.gov NCT00534911.

Figures

FIGURE 1
FIGURE 1
CBT associated with more significant improvement in somatic depressive symptoms in the presence of active CD compared with SNDT.

References

    1. Bennett DS. Depression among children with chronic medical problems: a meta-analysis. J Pediatr Psychol. 1994;19:149–169.
    1. Blackman JA, Conaway MR. Developmental, emotional and behavioral co-morbidities across the chronic health condition spectrum. J Pediatr Rehabil Med. 2013;6:63–71.
    1. Verhoof E, Maurice-Stam H, Heymans H, et al. Health-related quality of life, anxiety and depression in young adults with disability benefits due to childhood-onset somatic conditions. Child Adolesc Psychiatry Ment Health. 2013;7:12.
    1. Regueiro MD, Swoger JM. Clinical Challenges and Complications of IBD. Thorofare, NJ: SLACK Inc; 2013.
    1. Michail S, Ramsy M, Soliman E. Advances in inflammatory bowel diseases in children. Minerva Pediatr. 2012;64:257–270.
    1. Burke P, Meyer V, Kocoshis S, et al. Depression and anxiety in pediatric inflammatory bowel disease and cystic fibrosis. J Am Acad Child Adolesc Psychiatry. 1989;28:948–951.
    1. Szigethy E, Levy-Warren A, Whitton S, et al. Depressive symptoms and inflammatory bowel disease in children and adolescents: a cross-sectional study. J Pediatric Gastroenterology Nutrition. 2004;39:395–403.
    1. Greenley RN, Hommel KA, Nebel J, et al. A meta-analytic review of the psychosocial adjustment of youth with inflammatory bowel disease. J Pediatr Psychol. 2010;35:857–869.
    1. Bonaz BL, Bernstein CN. Brain-gut interactions in inflammatory bowel disease. Gastroenterology. 2013;144:36–49.
    1. Gabbay V, Klein RG, Alonso CM, et al. Immune system dysregulation in adolescent major depressive disorder. J Affect Disord. 2009;115:177–182.
    1. Mills NT, Scott JG, Wray NR, et al. Research review: the role of cytokines in depression in adolescents: a systematic review. J Child Psychol Psychiatry. 2013;54:816–835.
    1. Hood KK, Lawrence JM, Anderson A, et al. Metabolic and inflammatory links to depression in youth with diabetes. Diabetes Care. 2012;35:2443–2446.
    1. Shanahan L, Copeland WE, Worthman CM, et al. Children with both asthma and depression are at risk for heightened inflammation. J Pediatr. 2013.
    1. Dantzer R, Kelley KW. Twenty years of research on cytokine-induced sickness behavior. Brain Behav Immun. 2007;21:153–160.
    1. Biesmans S, Meert TF, Bouwknecht JA, et al. Systemic immune activation leads to neuroinflammation and sickness behavior in mice. Mediators Inflamm. 2013;2013:271359.
    1. Capuron L, Gumnick JF, Musselman DL, et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology. 2002;26:643–652.
    1. Tsuru S, Nomoto K, Taniguchi M, et al. Depression of protective mechanism during the early phase of a viral infection in tumor-bearing mice and prevention by PSK. Cancer Immunol Immunother. 1986;22:114–118.
    1. Bousvaros A, Antonioli DA, Colletti RB, et al. Differentiating ulcerative colitis from Crohn's disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America. J Pediatric Gastroenterology Nutrition. 2007;44:653–674.
    1. Ponder A, Long MD. A clinical review of recent findings in the epidemiology of inflammatory bowel disease. Clin Epidemiol. 2013;5:237–247.
    1. Szigethy E, Bujoreanu SI, Youk AO, et al. Randomized efficacy trial of two psychotherapies for depression in youth with inflammatory bowel disease. J Am Acad Child Adolesc Psychiatry. 2014;53:726–735.
    1. Szigethy E, Whitton SW, Levy-Warren A, et al. Cognitive-behavioral therapy for depression in adolescents with inflammatory bowel disease: a pilot study. J Am Acad Child Adolesc Psychiatry. 2004;43:1469–1477.
    1. Szigethy E, Kenney E, Carpenter J, et al. Cognitive-behavioral therapy for adolescents with inflammatory bowel disease and subsyndromal depression. J Am Acad Child Adolesc Psychiatry. 2007;46:1290–1298.
    1. Mrakotsky C, Forbes PW, Bernstein JH, et al. Acute cognitive and behavioral effects of systemic corticosteroids in children treated for inflammatory bowel disease. J Int Neuropsychol Soc. 2013;19:96–109.
    1. Kovacs M. The Children's Depression, Inventory (CDI). Psychopharmacol Bull. 1985;21:995–998.
    1. Kaufman J, Birmaher B, Brent D, et al. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry. 1997;36:980–988.
    1. American Psychiatric A, American Psychiatric Association. Task Force on D-I. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR. Washington, DC: American Psychiatric Association; 2000.
    1. Poznanski EO, Mokros HB. Children's Depression Rating Scale, Revised (CDRS-R) Manual. Los Angeles, CA: Western Psychological Services; 1996.
    1. Morrison KM, Goli A, Van Wagoner J, et al. Depressive symptoms in inner-city children with asthma. Prim Care Companion J Clin Psychiatry. 2002;4:174–177.
    1. Harms HK, Blomer R, Bertele-Harms RM, et al. A paediatric Crohn's disease activity index (PCDAI). Is it useful? Study Group on Crohn's Disease in Children and Adolescents. Acta Paediatr Suppl. 1994;83:22–26.
    1. Loonen HJ, Griffiths AM, Merkus MP, et al. A critical assessment of items on the Pediatric Crohn's Disease Activity Index. J Pediatric Gastroenterology Nutrition. 2003;36:90–95.
    1. Turner D, Griffiths AM, Walters TD, et al. Appraisal of the pediatric Crohn's disease activity index on four prospectively collected datasets: recommended cutoff values and clinimetric properties. Am J Gastroenterol. 2010;105:2085–2092.
    1. Szigethy E, Thompson R, Turner S, et al. Cognitive behavioral therapy for general medical conditions. In: E S, Weisz JR, Findling RL, eds. Cognitive Behavioral Therapy for Children and Adolescents. Washington, DC: American Psychiatric Publishing; 2012:331–382.
    1. Eisenberger NI, Berkman ET, Inagaki TK, et al. Inflammation-induced anhedonia: endotoxin reduces ventral striatum responses to reward. Biol Psychiatry. 2010;68:748–754.
    1. Stata Statistical Software: Release 12 [Computer Program]. College Station, TX: StataCorp LP; 2011.
    1. Goodhand JR, Wahed M, Mawdsley JE, et al. Mood disorders in inflammatory bowel disease: relation to diagnosis, disease activity, perceived stress, and other factors. Inflamm Bowel Dis. 2012.
    1. Szigethy EM, Youk AO, Benhayon D, et al. Depression subtypes in pediatric inflammatory bowel disease. J Pediatric Gastroenterology Nutrition. 2014;58:574–581.
    1. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry. 2009;65:732–741.
    1. Franzen PL, Buysse DJ, Rabinovitz M, et al. Poor sleep quality predicts onset of either major depression or subsyndromal depression with irritability during interferon-alpha treatment. Psychiatry Res. 2010;177:240–245.
    1. Spirito A, Esposito-Smythers C, Wolff J, et al. Cognitive-behavioral therapy for adolescent depression and suicidality. Child Adolesc Psychiatr Clin N Am. 2011;20:191–204.
    1. Raison CL, Rutherford RE, Woolwine BJ, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry. 2013;70:31–41.
    1. Ghia JE, Blennerhassett P, Kumar-Ondiveeran H, et al. The vagus nerve: a tonic inhibitory influence associated with inflammatory bowel disease in a murine model. Gastroenterology. 2006;131:1122–1130.
    1. Ghia JE, Blennerhassett P, Collins SM. Impaired parasympathetic function increases susceptibility to inflammatory bowel disease in a mouse model of depression. J Clin Invest. 2008;118:2209–2218.
    1. Koopman FA, Stoof SP, Straub RH, et al. Restoring the balance of the autonomic nervous system as an innovative approach to the treatment of rheumatoid arthritis. Mol Med. 2011;17:937–948.
    1. Ghia JE, Blennerhassett P, El-Sharkawy RT, et al. The protective effect of the vagus nerve in a murine model of chronic relapsing colitis. Am J Physiol Gastrointest Liver Physiol. 2007;293:G711–G718.
    1. Mawdsley J, Jenkins D, Macey M, et al. The effect of hypnosis on systemic and rectal mucosal measures of inflammation in ulcerative colitis. Am J Gastroenterol. 2008;103:1460–1469.
    1. Rosenkranz MA, Davidson RJ, Maccoon DG, et al. A comparison of mindfulness-based stress reduction and an active control in modulation of neurogenic inflammation. Brain Behav Immun. 2013;27:174–184.
    1. Schoen M, Nowack K. Reconditioning the stress response with hypnosis CD reduces the inflammatory cytokine IL-6 and influences resilience: a pilot study. Complement Ther Clin Pract. 2013;19:83–88.
    1. Rahimi HR, Shiri M, Razmi A. Antidepressants can treat inflammatory bowel disease through regulation of the nuclear factor-kappaB/nitric oxide pathway and inhibition of cytokine production: a hypothesis. World J Gastrointest Pharmacol Ther. 2012;3:83–85.
    1. Daneshmand A, Mohammadi H, Rahimian R, et al. Chronic lithium administration ameliorates 2,4,6-trinitrobenzene sulfonic acid-induced colitis in rats; potential role for adenosine triphosphate sensitive potassium channels. J Gastroenterol Hepatol. 26:1174–1181.
    1. Brustolim D, Ribeiro-dos-Santos R, Kast RE, et al. A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice. Int Immunopharmacol. 2006;6:903–907.
    1. Kane S, Altschuler EL, Kast RE. Crohn's disease remission on bupropion. Gastroenterology. 2003;125:1290.
    1. Kast R. Anti- and pro-inflammatory considerations in antidepressant use during medical illness: bupropion lowers and mirtazapine increases circulating tumor necrosis factor-alpha levels. Gen Hosp Psychiatry. 2003;25:495–496.
    1. Felger JC, Miller AH. Cytokine effects on the basal ganglia and dopamine function: the subcortical source of inflammatory malaise. Front Neuroendocrinol. 2012;33:315–327.
    1. Miller AH, Haroon E, Raison CL, et al. Cytokine targets in the brain: impact on neurotransmitters and neurocircuits. Depress Anxiety. 2013;30:297–306.
    1. Feise RJ. Do multiple outcome measures require p-value adjustment? BMC Med Res Methodol. 2002;2:8.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj